- Home
- LONA vs LPAA Comparison
LONA vs LPAA Comparison
Compare LONA & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LONA | LPAA |
|---|---|---|
| Founded | 2011 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 81.4M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LONA | LPAA |
|---|---|---|
| Price | $6.95 | $10.76 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 40.2K | 1.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $10.44 |
| 52 Week High | $14.21 | $11.67 |
Technical Indicators
Market Signals| Indicator | LONA | LPAA |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 46.59 |
| Support Level | $6.86 | $10.61 |
| Resistance Level | $8.57 | $10.79 |
| Average True Range (ATR) | 0.58 | 0.01 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 29.70 | 22.22 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.